PD-RX Pharmaceuticals Inc (PDRX)
5.50
0.00 (0.00%)
USD |
OTCM |
Apr 17, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | -- |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -8.33% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 61.69% |
Profile
| PD-RX Pharmaceuticals Inc provides and distributes a complete line of brand and generic pharmaceuticals, unit dose products, unit of use, injectables, creams, ointments, and medical and surgical supplies. |
| URL | https://www.pdrx.com |
| Investor Relations URL | N/A |
| HQ State/Province | Oklahoma |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Equity Style | N/A |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Dec. 13, 2018 |
Ratings
Profile
| PD-RX Pharmaceuticals Inc provides and distributes a complete line of brand and generic pharmaceuticals, unit dose products, unit of use, injectables, creams, ointments, and medical and surgical supplies. |
| URL | https://www.pdrx.com |
| Investor Relations URL | N/A |
| HQ State/Province | Oklahoma |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Equity Style | N/A |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Dec. 13, 2018 |